A randomized open-label study of guideline-driven antiemetic therapy versus single agent antiemetic therapy in patients with advanced cancer and nausea not related to anticancer treatment
Abstract Background Nausea/vomiting (N/V) not related to anti-cancer treatment is common in patients with advanced cancer. The standard approach to management is to define a dominant cause, and treat with an antiemetic selected through pathophysiologic knowledge of emetic pathways. High rates of N/V...
Main Authors: | Janet Hardy, Helen Skerman, Paul Glare, Jennifer Philip, Peter Hudson, Geoffrey Mitchell, Peter Martin, Odette Spruyt, David Currow, Patsy Yates |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12885-018-4404-8 |
Similar Items
-
An Evidence Practice Gap in Antiemetic Prescription with Chemotherapy
by: Chepsy C-Philip, et al.
Published: (2015-10-01) -
Dronabinol for chemotherapy-induced nausea and vomiting unresponsive to antiemetics
by: May MB, et al.
Published: (2016-05-01) -
Evaluating the antiemetic administration consistency to prevent chemotherapy-induced nausea and vomiting with the standard guidelines: a prospective observational study
by: Vazin A, et al.
Published: (2017-09-01) -
Therapeutic study of the nausea and vomiting caused by chemotherapy medications by olanzapine to triple antiemetic therapy in Iraqi cancer patients
by: Ghufran salah ahmed, et al.
Published: (2023-05-01) -
Pooled analysis of combination antiemetic therapy for chemotherapy-induced nausea and vomiting in patients with colorectal cancer treated with oxaliplatin-based chemotherapy of moderate emetic risk
by: Mototsugu Shimokawa, et al.
Published: (2021-10-01)